Pharmacogenomic tests in Oncology - finding the right dose
Brazilian Journal of Oncology, 2021 A pharmacogenetics/genomics (PGx) anticancer drug testing program is being developed by Kurtz and his group at the Brazilian National Cancer Institute (INCA).
Jeziel Basso, Gilberto Schwartsmann
doaj +1 more source
Change in hematologic indices over time in pediatric inflammatory bowel disease treated with azathioprine [PDF]
, 2010 Azathioprine leads to changes in mean corpuscular volume (MCV) and white blood cell (WBC) indices reflecting efficacy or toxicity. Understanding the interactions between bone marrow stem cells and azathioprine could highlight abnormal response patterns ...
A Timmer +18 more
core +2 more sources
Clinical application of high throughput molecular screening techniques for pharmacogenomics. [PDF]
, 2011 Genetic analysis is one of the fastest-growing areas of clinical diagnostics. Fortunately, as our knowledge of clinically relevant genetic variants rapidly expands, so does our ability to detect these variants in patient samples.
Schrijver, Iris, Wiita, Arun P
core +1 more source
Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology [PDF]
, 2019 The Clinical Laboratory Improvement Amendments (CLIA) of 1988 requires that pharmacogenetic genotyping methods need to be established according to technical standards and laboratory practice guidelines before testing can be offered to patients.
Kiel, Patrick J. +7 more
core +1 more source
Azathioprine‐induced pancytopenia: A case report
Rheumatology & Autoimmunity, 2022 Azathioprine (AZA) is commonly used as immunosuppressive therapy for autoimmune diseases, including systemic lupus erythematosus (SLE). Myelosuppression is a common side effect of AZA.
Keshav Raj Sigdel +8 more
doaj +1 more source
Pharmacogenomics in clinical practice: Biomarker information in Brazilian drug labels. [PDF]
Br J Clin PharmacolThis review examines the PGx annotations in package inserts (bulas in Brazilian Portuguese) approved by ANVISA, the Brazilian Health Regulatory Agency, for 19 gene–drug pairs with strong or moderate recommendations for initial dosing alteration in the CPIC (Clinical Pharmacogenetic Implementation Consortion) guidelines and PGx testing required or ...
Suarez-Kurtz G.
europepmc +2 more sources
Implementation of
British Journal of Clinical Pharmacology, 2014 The activity of the enzyme thiopurine methyltransferase (TPMT) is regulated by a common genetic polymorphism. One in 300 individuals lack enzyme activity and 11% are heterozygous for a variant low activity allele and have an intermediate activity. The thiopurine drugs azathioprine, mercaptopurine and thioguanine are substrates for TPMT; these drugs ...
openaire +2 more sources
Nomenclature for alleles of the thiopurine methyltransferase gene [PDF]
, 2013 The drug-metabolizing enzyme thiopurine methyltransferase (TPMT) has become one of the best examples of pharmacogenomics to be translated into routine clinical practice.
Ameyaw +53 more
core +2 more sources
Thiopurine methyltransferase polymorphisms in children with acute lymphoblastic leukemia
Indian Journal of Medical and Paediatric Oncology, 2014 Introduction: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. 6-mercaptopurine (6-MP) and methotrexate are backbone drugs for maintenance phase of treatment. Purine Analogs 6-MP/6-thioguanine/azathiopurine are metabolized to
Vijay Gandhi Linga +7 more
doaj +1 more source
Analysis of carrying clinically significant allelic variants of TPMT and DPYD genes associated with the response to drug therapy in cancer practice among 9 ethnic groups of the Russian Federation [PDF]
Терапевтический архив, 2020 Aim. To study the peculiarities of carrying clinically significant allelic variants of TPMT and DPYD genes associated with the response to drug therapy in cancer practice among 9 ethnic groups of the Russian Federation. Materials and methods.
K. B. Mirzaev +19 more
doaj +1 more source